American Factory Tracker
About
PharmaceuticalsWilmington, DelawareAnnounced Apr 29, 2025

Merck

See all projects by Merck →

Merck's Biologics Center of Excellence — a 470,000 sq ft biologics commercialization and launch facility for next-generation biologics including future U.S. KEYTRUDA production. Announced April 2025 with $1B+ investment and more than 500 full-time roles. Groundbreaking April 2025; laboratory expected to be operational by 2028, investigational-compound production anticipated to start by 2030.

Investment
$1.00B
Permanent jobs announced
500
Status
Under Construction
Expected opening
Jan 1, 2028
Why it matters

The pharmaceuticals context.

Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.

Project record

At a glance

Company
Merck
Industry
Pharmaceuticals
Location
Wilmington, Delaware
Investment
$1.00B
Permanent jobs announced
500
Status
Under Construction
Announced
Apr 29, 2025
Expected opening
Jan 1, 2028
Added to tracker
Apr 15, 2025
Sources

Official references

  • Primary source
    https://www.merck.com/news/merck-breaks-ground-on-new-1-billion-biologics-center-of-excellence-in-wilmington-delaware/
Related

Other projects to know

Across Pharmaceuticals
Back to the tracker/projects/merck-wilmington